Legal entity
Last mentioned: 5d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ip-patent is the sole category represented across all 1 tracked stories. NAFLD/NASH is most often covered alongside Dr. Eric Leire, which appears in 1 of these 1 story. NAFLD/NASH appears in 1 tracked Legal story from August 8, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NAFLD/NASH. Shared-story counts are live from our verified record — not editorial picks.
Genflow Announces Patent Progress
Genflow Biosciences issues a regulatory news release disclosing the USPTO publication and outlining its layered patent strategy across four families.
USPTO Publishes SIRT6 Patent Application
Patent application US 2026/0199524 A1, covering the SIRT6 variant for NAFLD/NASH, is published, initiating the examination process.
Genflow Biosciences' US patent publication marks a pivotal step in its layered IP strategy for the SIRT6 variant, with four patent families covering composition, delivery, and therapeutic indications, highlighting the company's defensive approach in longevity biotech.
NAFLD/NASH is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
